RENE ALAMO: Open Payments
NPI 1558083402 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$643 in 36 payments from 13 companies in 2025. Trend: 2023 $67 · 2024 $519 · 2025 $643
Food & beverage: $643
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $154 |
| Lilly USA, LLC | 2 | $124 |
| Vanda Pharmaceuticals Inc. | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Alkermes, Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| Exact Sciences Corporation | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
Products named: ZEPBOUND, VRAYLAR, FANAPT, QULIPTA, REXULTI, CAPLYTA, LYBALVI, Auvelity.
Industry payments across ID — which companies pay providers there.
